YERVOY®
(ipilimumab)

Patient Alert Card

Date of MMA approval: AUG 2020
Local approval number: 731MT2005891-01

Bristol Myers Squibb™

Important Information for Patients

Carry this card with you at all times to inform healthcare professionals that you are receiving treatment with YERVOY® alone.

If you have any signs or symptoms, tell your doctor right away.

POSSIBLE SIDE EFFECTS	
BOWEL AND STOMACH •diarrhoea (watery, loose or soft stools), bloody or dark-coloured stools •more frequent bowel movements than usual •pain or tenderness in your stomach or abdomen area, nausea, vomiting	**EYE** •redness in the eye •pain in the eye •vision problems or blurry vision
LIVER •eye or skin yellowing (jaundice) •pain on the right side of your stomach area •dark urine	**NERVES** •muscle weakness •numbness or tingling in legs, arms or face •dizziness, loss of consciousness or difficulty waking up
SKIN •skin rash with or without itching, dry skin •blisters and/or peeling of the skin, mouth sores •swelling of the face or lymph glands	**GENERAL** •fever, headache, tiredness •bleeding •behavioural changes (e.g. less sex drive, being irritable or forgetful) •dehydration, low blood pressure, shock

⚠ IMPORTANT

- Tell your doctor of any previous medical conditions.
- Early treatment of side effects reduces the likelihood that YERVOY® treatment will need to be temporarily or permanently stopped.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- DO NOT try to treat these symptoms yourself.
- Signs and symptoms may be delayed and may occur weeks to months after your last YERVOY® injection.

For more information, read the YERVOY® Package Leaflet at www.ema.europa.eu

My Doctor's Contact Information *(who prescribed YERVOY®)*
Name of Doctor:

Office Phone:

After-Hours Phone:

My Contact Information
My Name and Phone:

Caregiver Name and Phone (in case of emergency):

IMPORTANT Information for Healthcare Professionals

- This patient is treated with **YERVOY®** monotherapy.
- Immune-related adverse reactions (irARs) may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimise life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific irARs.
- Healthcare professionals should refer to the YERVOY® Summary of Product Characteristics (SmPC) at www.ema.europa.eu or call Medical Information on 00356 2397 6505 for more information.

The healthcare professional treating this patient with YERVOY® should complete the '**My Doctor's Contact Information**' section of this Patient Alert Card.